This is the second product Clinigen has licensed to Cumberland under the strategic alliance established in 2015, following the launch of Ethyol (amifostine) in the U.S. in September 2016.
The company acquired about 8.4 percent of the outstanding shares of common stock in Arrowhead Since the capital raise of May 2015, Silence has been actively evaluating a
Subject to stockholder approval, the combined company will advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product
Lucentis is the first FDA-approved anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV in the U.S. This is the fifth FDA-approved indication for Lucentis since the medicine
PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient’s red
SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called
Under the terms of the development agreement, PvP will conduct all research and development through phase 1 proof-of-principle studies per a pre-defined development plan. Takeda will fund $35
Meeting minutes received from the FDA’s Division of Anti-Infective Products confirmed key elements of the company’s overall plan for benznidazole, including: The company’s proposed 505(b)(2) approach to demonstrate
Microbion, co-located in Vancouver, BC and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of hard to treat and antibiotic-resistant infections. Microbion's lead compound,
The research could point to new ways to treat or prevent the spread of cancer cells, which is the biggest cause of cancer death. Scientists at The Institute
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.